EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Propranolol for Tremors in Spinocerebellar Ataxia Type 12: A Randomized Clinical Trial

Prachi Mohapatra iD, Achal Kumar Srivastava iD, Divyani Garg iD, Ayush Agarwal iD, Divya M Radhakrishnan iD, Awadh Kishor Pandit, Pooja Gupta, Sahaj Agrawal, Ashish Datt Upadhyay

Movement Disorders · 2025

DOI: 10.1002/mds.70115 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, 2025. Verfasst von Prachi Mohapatra und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Propranolol, Tremor, Spinocerebellar Ataxias, Adrenergic beta-Antagonists. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Spinocerebellar ataxia type 12 (SCA12) is a neurodegenerative disorder with prominent upper limb tremors. No trials have evaluated tremor‐targeted therapies in this population.

Objectives

We evaluated long‐acting propranolol for efficacy and safety in reducing tremors and improving ataxia and quality of life in SCA12.

Methods

In this single‐center, randomized, double‐blind, placebo‐controlled trial, 60 genetically confirmed SCA12 patients (aged 18–65 years; TETRAS PS [The Essential Tremor Rating Assessment Scale Performance Subscale] upper limb component ≥2) were randomized 1:1 to receive extended‐release propranolol or placebo. Propranolol was escalated by 40 mg/week (placebo by one tablet/week) up to 240 mg/day, limiting side effects or ≥30% reduction in TETRAS PS/ADL (Activities‐of‐Daily‐Living Subscale) + PS. The stable dose was continued for 8 weeks (maintenance phase). Primary outcomes were changes from baseline in TETRAS PS and ADL + PS at maintenance weeks 4 and 8. Secondary outcomes included changes in the Scale for the Assessment and Rating of Ataxia (SARA), RAND 36‐Item Short‐Form Health Survey (SF‐36) domains, and accelerometric tremor parameters.

Results

Propranolol significantly reduced TETRAS PS (LSM ± SE: −4.4 ± 0.3 at week 4; −4.42 ± 0.4 at week 8) and ADL + PS (−5.5 ± 0.63 at week 4; −5.56 ± 0.62 at week 8; P < 0.001 vs. placebo). Significant improvements were also noted in SARA and five of nine SF‐36 domains at both time points. Accelerometry confirmed reductions in tremor peak frequency and power in all positions except rest. Fatigue and headache were the commonest adverse effects, with no discontinuations due to adverse events.

Conclusion

Propranolol effectively reduced tremors and improved quality of life in SCA12, with good tolerability. © 2025 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropranololTremorSpinocerebellar AtaxiasAdrenergic beta-AntagonistsHumansMaleFemaleMiddle AgedAdultDouble-Blind MethodQuality of LifeAgedYoung AdultAdolescentTreatment OutcomeActivities of Daily Living

Stichwörter der Autor:innen

The Essential Tremor Rating Assessment Scalebeta‐blockerspropranololspinocerebellar ataxia type 12tremor

Substanzen

PropranololAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
  • Clinical Research Unit, All India Institute of Medical Sciences, New Delhi, India.

ORCID-Profile: Prachi Mohapatra, Achal Kumar Srivastava, Divyani Garg, Ayush Agarwal, Divya M Radhakrishnan

Zitieren

APA

Mohapatra, P., Kumar Srivastava, A., Garg, D., Agarwal, A., Radhakrishnan, D. M., Pandit, A. K., Gupta, P., Agrawal, S., & Upadhyay, A. D. (2025). Propranolol for Tremors in Spinocerebellar Ataxia Type 12: A Randomized Clinical Trial. Movement Disorders. https://doi.org/10.1002/mds.70115

Vancouver

Mohapatra P, Kumar Srivastava A, Garg D, Agarwal A, Radhakrishnan DM, Pandit AK, et al. Propranolol for Tremors in Spinocerebellar Ataxia Type 12: A Randomized Clinical Trial. Movement Disorders. 2025. doi:10.1002/mds.70115

BibTeX
@article{Mohapatra2025,
  author = {Mohapatra, Prachi and Kumar Srivastava, Achal and Garg, Divyani and Agarwal, Ayush and Radhakrishnan, Divya M and Pandit, Awadh Kishor and Gupta, Pooja and Agrawal, Sahaj and Upadhyay, Ashish Datt},
  title = {Propranolol for Tremors in Spinocerebellar Ataxia Type 12: A Randomized Clinical Trial},
  journal = {Movement Disorders},
  year = {2025},
  doi = {10.1002/mds.70115}
}
Kostenlos starten →